US FDA clarifies how to ensure medtech trials comply with regulations
This article was originally published in Clinica
Executive Summary
The US Food and Drug Administration has issued a guidance document that clarifies how institutional review boards (IRBs), clinical investigators and medical device and drug sponsors can ensure that clinical trials of healthcare products comply with regulations and pose minimum risk to human subjects.